According to the newly adopted protocols by the Ministry of Health, a pharmaceutical company is permitted to bypass the standard three-phase clinical trial only if the medication in question targets a designated rare disease or has already received full regulatory approval in a recognized partner nation.
Which one of the following logically follows from the Ministry of Health's protocols?
- If a medication neither targets a designated rare disease nor has received full regulatory approval in a recognized partner nation, then the pharmaceutical company is not permitted to bypass the standard three-phase clinical trial.Cevap
- BIf a medication targets a designated rare disease or has received full regulatory approval in a recognized partner nation, then the pharmaceutical company is permitted to bypass the standard three-phase clinical trial.
- CIf a pharmaceutical company is not permitted to bypass the standard three-phase clinical trial, it must be the case that the medication neither targets a designated rare disease nor has received full regulatory approval in a recognized partner nation.
- DIf a medication does not target a designated rare disease, or if it lacks full regulatory approval in a recognized partner nation, then the pharmaceutical company is not permitted to bypass the standard three-phase clinical trial.
- EA pharmaceutical company is permitted to bypass the standard three-phase clinical trial if the medication in question both targets a designated rare disease and has received full regulatory approval in a recognized partner nation.
Cevap
If a medication neither targets a designated rare disease nor has received full regulatory approval in a recognized partner nation, then the pharmaceutical company is not permitted to bypass the standard three-phase clinical trial.
This option accurately presents the logically valid contrapositive of the stimulus. The original statement is structured as: Bypass -> (Rare Disease OR Partner Approval). The contrapositive requires negating both sides and reversing the logical arrow. Crucially, by De Morgan's laws, negating a disjunction (Rare Disease OR Partner Approval) creates a conjunction (NOT Rare Disease AND NOT Partner Approval). Therefore, if a medication lacks both required criteria, the company is absolutely not permitted to bypass the clinical trials.
Adım Adım Çözüm
Anahtar Kavram
Forming contrapositives of compound conditional statements using De Morgan's laws.
Tahmini Süre:1m 30s